IFNA1 and Cirrhosis: Glecaprevir/pibrentasvir (GLE/PIB) is a fixed dose, once-daily, all-oral combination DAA therapy approved by the European Medicines Agency to treat chronic HCV infection (genotypes (GT) 1–6) over 8 weeks in treatment-naïve (TN) patients without cirrhosis (NC), or with compensated cirrhosis (CC) and GT1, 2, 4–6 in pegylated-interferon- (peg-IFN) and/or sofosbuvir-experienced NC patients; 12 weeks for GT1, 2, 4–6 in peg-IFN- and/or sofosbuvir-experienced patients with CC; and 16 weeks for GT3 in peg-IFN- and/or sofosbuvir-experienced patients regardless of cirrhosis [9].